SG11201909983QA - Method of determining expression level of t315i variant of abl1 - Google Patents

Method of determining expression level of t315i variant of abl1

Info

Publication number
SG11201909983QA
SG11201909983QA SG11201909983QA SG11201909983QA SG 11201909983Q A SG11201909983Q A SG 11201909983QA SG 11201909983Q A SG11201909983Q A SG 11201909983QA SG 11201909983Q A SG11201909983Q A SG 11201909983QA
Authority
SG
Singapore
Prior art keywords
abl1
reverse
primer
variant
expression level
Prior art date
Application number
Inventor
Kiyonori Katsuragi
Hideaki Tanaka
Ryuta Ito
Daisuke Koga
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG11201909983QA publication Critical patent/SG11201909983QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)

Abstract

OF DISCLOSURE The disclosure provides .a method comprising () reverse- transcribing an RNA sample obtained from the subject in the presence of .a modified nucleic acid complementary to a Tegion comprising the position of the.T315I mutation of a wild-type ABL1 mRNA'by using (a) a reverse-primer that hybridizes to an ABL1 mRNA in a region downstream from the position of the T315I mutation and (b) a reverse primer that hybridizes to an ABL1 mRNA in a region upstream from the position of the T315I mutation in one container; and (2) calculating the expression level of the T315I variant of ABL1 on the basis of the ratio of the reverse transcript generated with the primer (a) to the reverse transcript'generated with the primer (b), as well as a kit for condtcting the method. 46
SG11201909983Q 2017-04-26 2018-04-25 Method of determining expression level of t315i variant of abl1 SG11201909983QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017087578 2017-04-26
PCT/JP2018/016748 WO2018199136A1 (en) 2017-04-26 2018-04-25 Method for measuring expression level of abl1 t315i mutation

Publications (1)

Publication Number Publication Date
SG11201909983QA true SG11201909983QA (en) 2019-11-28

Family

ID=63919184

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912849TA SG10201912849TA (en) 2017-04-26 2018-04-25 Method of determining expression level of t315i variant of abl1
SG11201909983Q SG11201909983QA (en) 2017-04-26 2018-04-25 Method of determining expression level of t315i variant of abl1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912849TA SG10201912849TA (en) 2017-04-26 2018-04-25 Method of determining expression level of t315i variant of abl1

Country Status (6)

Country Link
JP (1) JPWO2018199136A1 (en)
KR (1) KR20200002933A (en)
CN (1) CN110997938A (en)
PH (1) PH12019502417A1 (en)
SG (2) SG10201912849TA (en)
WO (1) WO2018199136A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111321200A (en) * 2020-02-28 2020-06-23 广州安镝声生物医药科技有限公司 Extracellular ABL1 kinase activity detection kit and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211483A1 (en) * 2002-05-09 2003-11-13 Schroeder Benjamin G. Methods for the enrichment of low-abundance polynucleotides
JP5221248B2 (en) * 2008-08-26 2013-06-26 株式会社日立ハイテクノロジーズ Method for preparing a cDNA library with a reduced content of cDNA clones derived from highly expressed genes
TWI541507B (en) * 2009-09-11 2016-07-11 香港中文大學 Methods for assessing liver pathologies
KR101875199B1 (en) * 2010-11-11 2018-07-06 주식회사 파나진 Methods and kits for the detection of BCR-ABL fusion gene mutant using PNA mediated Real-time PCR clamping
CN102676638B (en) * 2011-03-08 2014-06-04 苏州大学附属第一医院 Method and kit for detecting drug-resistance mutation site of ABL kinase domain of BCR/ABL fusion gene
JP6531312B2 (en) * 2014-10-17 2019-06-19 東洋鋼鈑株式会社 Method for detecting BCR-ABL inhibitor resistance related mutation and data acquisition method for predicting BCR-ABL inhibitor resistance using the same
CN105349681A (en) * 2015-12-07 2016-02-24 湖南圣维基因科技有限公司 BCR-ABL fusion gene T315I mutation fluorescent PCR detection kit
RU2609641C1 (en) * 2015-12-07 2017-02-02 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Method of analysis of somatic mutations in the bcr/abl chimeric gene using rt-pcr and subsequent hybridization with oligonucleotide biological microchip (biochip)
CN105441568B (en) * 2016-01-06 2019-01-08 武汉海吉力生物科技有限公司 For detecting primer, probe and the kit of mankind BCR-ABL fusion T315I mutation

Also Published As

Publication number Publication date
KR20200002933A (en) 2020-01-08
PH12019502417A1 (en) 2020-10-19
SG10201912849TA (en) 2020-02-27
WO2018199136A1 (en) 2018-11-01
CN110997938A (en) 2020-04-10
JPWO2018199136A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2021011031A (en) Fed-batch in vitro transcription process.
EP4328322A3 (en) Probe library construction
MX2019005199A (en) Methods for assessing risk using total and specific cell-free dna.
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
SG10201804519RA (en) Methods and systems for detecting genetic variants
EP4306659A3 (en) A method and kit for determining the tissue or cell origin of dna
WO2014052260A3 (en) Systems, methods and interfaces for evaluating an online entity presence
MX344181B (en) Determining liquid phase turbidity of multiphase wastewater.
EP4269610A3 (en) Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
NZ725789A (en) Dre4 nucleic acid molecules that confer resistance to coleopteran pests
MX2016008261A (en) Ras opposite (rop) and related nucleic acid molecules that confer resistance to coleopteran and/or hemipteran pests.
BR112017007253A2 (en) system and method for ammonia oxidation
MX2017007534A (en) Parental rnai suppression of chromatin remodeling genes to control coleopteran pests.
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
MX2016008263A (en) Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests.
PH12017501090A1 (en) Parental rnai suppression of kruppel gene to control coleopteran pests
MX2020002826A (en) Detection of recombinase polymerase amplification using dual-hapten probe.
MX2017011445A (en) Rna polymerase ii33 nucleic acid molecules to control insect pests.
SG11201909983QA (en) Method of determining expression level of t315i variant of abl1
EP4012049A3 (en) Methods for determining responsiveness to mek/erk inhibitors
WO2017074780A3 (en) Nucleic acid molecules that confer resistance to coleopteran pests
WO2013088140A3 (en) Tenascin-c and use thereof in rheumatoid arthritis
NZ603088A (en) Methods for identifying compositions that alter wildtype expression of genes and proteins in a plant cell
MX2017007536A (en) Parental rnai suppression of kruppel gene to control hemipteran pests.
Kondrlová et al. GIS application in sediment delivery estimation: comparison of two model approaches